MY194819A - Bone-targeting antibodies - Google Patents

Bone-targeting antibodies

Info

Publication number
MY194819A
MY194819A MYPI2019006821A MYPI2019006821A MY194819A MY 194819 A MY194819 A MY 194819A MY PI2019006821 A MYPI2019006821 A MY PI2019006821A MY PI2019006821 A MYPI2019006821 A MY PI2019006821A MY 194819 A MY194819 A MY 194819A
Authority
MY
Malaysia
Prior art keywords
bone
antibodies
targeting antibodies
fragments
poly
Prior art date
Application number
MYPI2019006821A
Other languages
English (en)
Inventor
Huawei Qiu
Sunghae Park
James Stefano
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MY194819A publication Critical patent/MY194819A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2019006821A 2017-01-20 2018-01-19 Bone-targeting antibodies MY194819A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20
PCT/US2018/014350 WO2018136698A2 (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Publications (1)

Publication Number Publication Date
MY194819A true MY194819A (en) 2022-12-17

Family

ID=61581744

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2022003998A MY207919A (en) 2017-01-20 2018-01-19 Bone-targeting antibodies
MYPI2019006821A MY194819A (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MYPI2022003998A MY207919A (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Country Status (17)

Country Link
US (3) US10844115B2 (enExample)
EP (1) EP3571226A2 (enExample)
JP (3) JP7227138B2 (enExample)
KR (3) KR20250012197A (enExample)
CN (2) CN118121696A (enExample)
AR (1) AR110755A1 (enExample)
AU (1) AU2018210270A1 (enExample)
BR (1) BR112019013986A2 (enExample)
CA (1) CA3050884A1 (enExample)
IL (2) IL317592A (enExample)
MX (2) MX2019008549A (enExample)
MY (2) MY207919A (enExample)
SG (1) SG11201906663VA (enExample)
TW (3) TW202421659A (enExample)
UY (1) UY37576A (enExample)
WO (1) WO2018136698A2 (enExample)
ZA (1) ZA201907673B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017310344A1 (en) * 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
EP3820575A1 (en) * 2018-07-10 2021-05-19 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
EP3884066A2 (en) * 2018-11-19 2021-09-29 Biocartis NV Enhanced detection of low-copy-number nucleic acids in an integrated workflow
EP4334347A1 (en) 2021-05-07 2024-03-13 Baylor College of Medicine Treatment of moderate-to-severe osteogenesis imperfecta
CA3226401A1 (en) * 2021-07-20 2023-01-26 William Marsh Rice University Engineered compositions for bone-targeted therapy
IL312489A (en) * 2021-11-01 2024-07-01 Genzyme Corp Treatment of defective bone formation
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
BRPI9707379B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
PL1850873T3 (pl) 2005-02-08 2019-06-28 Genzyme Corporation Przeciwciała przeciwko tgfbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
BRPI0620240A2 (pt) * 2005-12-23 2011-11-08 Lilly Co Eli anticorpo monoclonal, uso do mesmo e composição farmaceutica
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US20110189206A1 (en) * 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
ES2458665T5 (es) * 2008-12-22 2021-06-30 Novo Nordisk As Anticuerpos contra el inhibidor de la vía del factor tisular
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
BR112013030958B1 (pt) 2011-06-03 2022-02-08 Xoma Technology Ltd Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
JP6180408B2 (ja) * 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013178736A1 (en) 2012-05-31 2013-12-05 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2908913B1 (en) 2012-10-17 2018-10-03 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
CN105229028B (zh) 2013-03-20 2019-11-08 建新公司 用于治疗成骨不全的方法
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
SG10201808519VA (en) 2013-12-17 2018-10-30 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015140150A1 (en) * 2014-03-17 2015-09-24 Piotr Jachimczak Combination for use in a method of treating cancer
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
DK3283107T3 (da) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Sammensætninger omfattende en kombination af ipilimumab og nivolumab
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
AU2017310344A1 (en) 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
TW202421659A (zh) * 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途

Also Published As

Publication number Publication date
TW202330597A (zh) 2023-08-01
UY37576A (es) 2018-10-31
US12098194B2 (en) 2024-09-24
KR20230172039A (ko) 2023-12-21
KR102755284B1 (ko) 2025-01-22
US20180208650A1 (en) 2018-07-26
AR110755A1 (es) 2019-05-02
KR102613463B1 (ko) 2023-12-15
MX2022008073A (es) 2022-07-27
KR20250012197A (ko) 2025-01-23
TWI832600B (zh) 2024-02-11
ZA201907673B (en) 2021-05-26
JP7227138B2 (ja) 2023-02-21
TW201839013A (zh) 2018-11-01
CN111032690A (zh) 2020-04-17
RU2019126026A3 (enExample) 2021-11-09
AU2018210270A1 (en) 2019-09-05
IL317592A (en) 2025-02-01
WO2018136698A3 (en) 2018-08-30
US10844115B2 (en) 2020-11-24
WO2018136698A2 (en) 2018-07-26
CN111032690B (zh) 2024-03-26
MY207919A (en) 2025-03-27
TWI788321B (zh) 2023-01-01
JP2023058590A (ja) 2023-04-25
IL268114A (en) 2019-09-26
SG11201906663VA (en) 2019-08-27
KR20190105236A (ko) 2019-09-16
JP2020505919A (ja) 2020-02-27
JP2025028981A (ja) 2025-03-05
MX2019008549A (es) 2019-09-11
JP7597836B2 (ja) 2024-12-10
US20210163584A1 (en) 2021-06-03
US20250074975A1 (en) 2025-03-06
CN118121696A (zh) 2024-06-04
TW202421659A (zh) 2024-06-01
CA3050884A1 (en) 2018-07-26
IL268114B2 (en) 2025-05-01
EP3571226A2 (en) 2019-11-27
RU2019126026A (ru) 2021-02-20
BR112019013986A2 (pt) 2020-03-03
IL268114B1 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MY194819A (en) Bone-targeting antibodies
ZA201904725B (en) Personalised immunogenic peptide identification platform
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2019007020A (es) Anticuerpos il-11.
MY191030A (en) Gdf15 fusion proteins and uses thereof
EP4599780A3 (en) Matrix implant
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
MX2017015927A (es) Fragmentos mutantes de proteina ras.
EP4442268A3 (en) Ctla-4 variant immunomodulatory proteins and uses thereof
PH12017502213A1 (en) Compositions and methods for treating celiac sprue disease
IL272931A (en) Peptide conjugates, conjugation process and their uses
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MY195726A (en) Steviol Glycoside Transport
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
EP4282960A3 (en) Modified lipase and use thereof
PH12018500468A1 (en) Fusion protein
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
PH12020551582A1 (en) Lfa3 variants and compositions and uses thereof
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
PH12019501164A1 (en) Trehalose phosphorylase
WO2019147979A3 (en) Peptides for angiogenic therapy
MX2020002382A (es) Métodos y composiciones para mejorar la expresión de proteínas recombinantes.
SG10201806532RA (en) Proteins targeting orthologs
WO2019103512A3 (ko) 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질